Cardiology

Evinacumab cuts cholesterol levels by half in patients with HoFH

The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol to near-normal levels among patients with a rare cholesterol disorder, meeting the primary endpoint in the first randomized placebo-controlled ...

Other

Novartis says to buy Medicines Company for $9.7 bn

Swiss pharmaceuticals giant Novartis announced over the weekend it would dish out $9.7 billion (8.8 billion euros) to acquire US firm Medicines Company, in a move aimed at boosting its cardiovascular treatment portfolio.

page 10 from 33